Silk Road Medical Inc Cashflow Statement

Ask AI

Overview Financial Statements SEC Filings Executives News Red Flags Capital Raising Ownership Insider Transactions Congressional Trades

Financial Statements

Income Statement Balance Sheet Cashflow Statement

Statements of Cash Flows

In millions of USD, except per-share amounts

	FY2023 12 months to Dec 31, 2023	FY2022 12 months to Dec 31, 2022	FY2021 12 months to Dec 31, 2021	FY2020 12 months to Dec 31, 2020	FY2019 12 months to Dec 31, 2019
Cash flows from operating activities
Net loss
Adjustments to reconcile net loss to net cash used in operating activities:
Depreciation and amortization expense
Stock-based compensation expense
Change in fair value of redeemable convertible preferred stock warrant liability
Amortization of premiums (accretion of discounts) on investments, net
Amortization of debt discount and debt issuance costs
Amortization of right-of-use asset
Non-cash interest expense
Loss on extinguishment of debt
Loss on disposal of property and equipment
Provision for (recovery of) doubtful accounts receivable
Provision for excess and obsolete inventories

Changes in operating assets and liabilities:
Accounts receivable
Inventories
Prepaid expenses and other current assets
Other assets
Accounts payable
Accrued liabilities
Other liabilities
Repayment of interest paid in kind

Net cash used in operating activities
Cash flows from investing activities
Purchases of property and equipment
Proceeds from sale of property and equipment
Purchases of investments
Proceeds from maturity of investments
Net cash provided by (used in) investing activities
Cash flows from financing activities
Proceeds from public offerings, net of underwriting discount, commissions and offering costs paid
Proceeds from long-term debt, net
Proceeds from issuance of common stock
Proceeds from exercise of warrants
Redeemable convertible preferred stock warrants outstanding
Common stock warrants outstanding
Principal repayment of long-term debt
Payments of prepayment penalty and lender fees
Proceeds from disgorgement of short-swing profits, net
Net cash provided by financing activities

Net change in cash, cash equivalents and restricted cash
Cash, cash equivalents and restricted cash, beginning of year
Cash, cash equivalents and restricted cash, end of year
Supplemental disclosure of cash flow information
Cash paid for interest
Noncash investing and financing activities:
Accounts payable and accrued liabilities for purchases of property and equipment
Landlord paid tenant improvements
Unpaid deferred offering costs
Net exercise of redeemable convertible preferred stock warrants to preferred stock
Conversion of redeemable convertible preferred stock to common stock upon initial public offering

Comments